Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

This study has been completed.
Sponsor:
Information provided by:
German CLL Study Group
ClinicalTrials.gov Identifier:
NCT00278213
First received: January 16, 2006
Last updated: September 23, 2016
Last verified: September 2016